CellAegies was a private medical device company based in Toronto, Canada. The company developed the autoRIC Device, an automated, non-invasive technology designed to deliver Remote Ischemic Condition (RIC) therapy. The therapy aimed to protect the heart and other organs from ischemia and reperfusion injury.
Limb ischemia
CTI LSF II
Lead
Director
February 10, 2017
Liquidated in 2019
Series C
CellAegis obtained Health Canada authorization and CE mark approval in Europe, and obtaining FDA approval would significant increase the company value
March 14, 2017
